{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-031590","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2025-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.429518+00:00","generated_at":"2026-05-23T15:33:07.061640+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"INmune Bio partners with CGT Catapult to scale CORDStrom manufacturing for commercial readiness","bullets":["Partnership with Cell and Gene Therapy Catapult aims to establish large-scale commercial manufacturing for cell therapy platforms.","Initial focus on scaling CORDStrom for RDEB; Phase 2 trial showed reduced pain/itch and improved skin integrity.","INmune estimates 4,000 children with intermediate-to-severe RDEB in US/UK/EU could benefit from CORDStrom.","Following CORDStrom, INmune plans to transition INKmune production to same facility for solid tumor trials.","Manufacturing will leverage CGT Catapult's Stevenage Innovation Centre and existing Royal Free Hospital base."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-031590","json":"https://secwatch.observer/filing/0001213900-25-031590.json","markdown":"https://secwatch.observer/filing/0001213900-25-031590.md","text":"https://secwatch.observer/filing/0001213900-25-031590.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025031590/0001213900-25-031590-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025031590/ea0238180-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T15:33:07.061640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}